Health
globalreutersOctober 4, 20241 Mins read
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
globalreutersOctober 4, 20241 Mins read 
Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion.
The post Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M appeared first on MedCity News.
Related Articles
Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?
Cost effectiveness analyses (CEA) aim to examine how a new health technologies...
5 Interesting Companies I Saw at HLTH
I met a mix of biotech and healthtech companies at HLTH affecting...
Patty Hayward, TalkDesk
Patty Hayward is GM of Healthcare and Life Sciences at TalkDesk. TalkDesk...
How chatbots are enhancing patient care
Consumers have come to expect options when communicating with the companies they...
Leave a comment